Insider buying last 90 days
No open-market insider purchases were filed for PRAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Praxis reported third-quarter 2026 results this week, posting a net loss of $94.2 million against $73.9 million a year prior, attributed to higher general and administrative costs, while noting that $1.3 billion in cash and investments is expected to fund operations into 2028. The update also reaffirmed ongoing FDA reviews for relutrigine and ulixacaltamide, with PDUFA target action dates in late 2026 and early 2027 respectively. Separately, the company disclosed inducement grants of restricted stock units to new non-executive employees under its 2024 Inducement Plan.
Shares closed at $332.97, up 19.9% on the day, sitting above both the 50-day average of $291.50 and the 200-day average of $314.06. The GekkoIndex reading stands at 48, placing the stock in the Neutral zone after a five-point change of -10.3. Price remains 14.3% below Gekko Fair Value of $388.55.
Looking ahead, no confirmed earnings date is currently on the calendar, with the last report filed 6 August 2026. Smart-money activity over the past 90 days shows one Congressional buy and no sales. Seasonality data show that, from this point in the calendar, the next 20 trading days have averaged a gain of 11.1% over five years, though they rose in only 2 of those years. Analyst coverage includes 11 buy ratings and 1 hold among 12 firms, with a consensus target of $650 reflecting 95.2% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Praxis Precision Medicines scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $328.13 sits between the 50-day ($289.90) and 200-day ($314.58) averages, or the averages disagree.
See the chart47.8, Neutral
Reading 47.8 is in the Neutral zone.
See the GekkoIndex18.0% below
Price is 18% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+10.9% on average
From this point in the calendar, the next 20 trading days averaged +10.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Praxis Precision Medicines closed at $328.13 on Nov 13, 2026, +78.7% over the past year, inside a 52-week range of $160.11 to $392.70.
Use the left and right arrow keys to read daily values.
Put PRAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Praxis Precision Medicines works on drug candidates for disorders of the central nervous system linked to imbalances in neuronal signaling, and has not yet brought a product to market. Its furthest-along programs are PRAX-114, a compound acting on the GABAA receptor being tested in mid-stage trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor being studied for essential tremor. It is also testing PRAX-562 for pediatric epilepsy and adult headache conditions, and developing genetic-targeted therapies for SCN2A and KCNT1 forms of epilepsy.
Its pipeline is built in part through outside partnerships rather than solely in-house work. Praxis has a licensing and cooperation agreement with RogCon, a license with Purdue Neuroscience Company, a research and licensing collaboration with Ionis Pharmaceuticals, and a joint effort with The Florey Institute to develop additional antisense therapies.
The company was founded in 2015 and is headquartered in Boston, Massachusetts. Its shares are listed on the NASDAQ under the ticker PRAX.
Praxis Precision Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.8, in the Neutral zone, down 10.4 points over five sessions.
Down 10.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 51 | Not available | |||
| Accumulation | 166 | +1.6% | +8.7% | ||
| Neutral (current zone) | 433 | +3.4% | +14.0% | ||
| Distribution | 47 | +1.3% | −2.9% | ||
| Selling | 5 | Too few readings yet | |||
Average PRAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Praxis Precision Medicines trades 18.0% below Gekko Fair Value of $400.12, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Praxis Precision Medicines shares are worth, recalculated every trading day.
$400.12
Gekko Fair Value, Nov 14, 2026
18.0% Undervalued
At the end of Aug 2026 the price was 34.2% below the estimate.
No open-market insider purchases were filed for Praxis Precision Medicines, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PRAX in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 29 |
From congressional disclosures, which report amounts as ranges.
Praxis Precision Medicines has been buying back its own shares.
From company filings.
Praxis Precision Medicines reports on Feb 18, 2027, before the open (95 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 18, 2027
Expected before the open, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$2.87 est −$3.67 | — est $1.25M | +13.0% |
| May 7, 2026 | −$3.20 est −$3.68 | — est $100K | −2.4% |
| Feb 19, 2026 | −$3.50 est −$3.13 | — est $67K | +1.9% |
| Nov 5, 2025 | −$3.36 est −$3.45 | — est $256K | +0.3% |
| Aug 4, 2025 | −$3.31 est −$3.36 | — est $59K | −11.6% |
| May 2, 2025 | −$3.29 est −$3.21 | — est $199K | +2.4% |
| Feb 28, 2025 | −$2.94 est −$2.82 | $7.46M est $298K | −48.4% |
| Nov 6, 2024 | −$2.75 est −$1.95 | — | +3.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Praxis Precision Medicines is $661.75, +101.7% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Piper Sandler | $1,200 | +265.7% |
| Nov 13 | H.C. Wainwright | $1,201 | +266.0% |
| Nov 12 | RBC Capital | $478 | +45.7% |
| Nov 10 | Oppenheimer | $650 | +98.1% |
| Nov 10 | JonesTrading | $534 | +62.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Praxis Precision Medicines averaged +10.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −4.5% | 1 of 5 |
| Next 10 trading days | +2.4% | 2 of 5 |
| Next 15 trading days | +11.3% | 2 of 5 |
| Next 20 trading days | +10.9% | 3 of 5 |
| Next 30 trading days | +22.3% | 3 of 5 |
For scale, PRAX’s typical 20-trading-day move in either direction is about 15.6%.
Praxis Precision Medicines’s market cap is $9.17B and revenue of $7.46M over the last twelve months.
Coverage of Praxis Precision Medicines this week reads neutral: 3 positive, 4 neutral and 0 negative headlines.
Praxis Precision Medicines’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Praxis Precision Medicines’s market cap is $9.17B at the Nov 13, 2026 close of $328.13, with 27.95M shares outstanding.
The consensus analyst 12-month price target for Praxis Precision Medicines is $661.75, +101.7% from the last close. Of the 13 firms that rated the stock in the last 90 days, 12 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Praxis Precision Medicines is undervalued: the Nov 13, 2026 close of $328.13 is 18.0% below Gekko Fair Value of $400.12. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Praxis Precision Medicines is expected to report on Feb 18, 2027, before the market opens (95 days away). Analysts expect earnings of −$4.08 per share on revenue of $377K. Praxis Precision Medicines beat the earnings estimate in 4 of its last 8 reports, moving 10.5% on average across the report.
Praxis Precision Medicines’s 52-week high is $392.70 and its 52-week low is $160.11; it closed at $328.13 on Nov 13, 2026, +78.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.